Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer

BACKGROUND: Several oncogenes and onco-suppressor genes have been implicated in epithelial ovarian carcinogenesis, but their clinical significance is not clear and conflicting data have been found in various studies. PATIENTS AND METHODS: The immunohistochemical expression of HER-2, p53 and Bcl-2 proteins was investigated in a cohort of 95 patients with advanced epithelial ovarian cancer (stages IIc-IV). These patients participated in a phase III randomized clinical trial and were treated either with paclitaxel/carboplatin, orpaclitaxel/carboplatin alternating with paclitaxel/cisplatin. RESULTS: Positive immunostaining for HER-2, p53 and Bcl-2 proteins was found in 18%, 70.5% and 69.5% of the cases, respectively. In multivariate analysis, older patients (< 63 vs. > or = 63 years, p < 0.001), worse grade (I-II vs. III, p = 0.04) and p53 expression (negative vs. positive, p = 0.002) were significant prognostic factors independently associated with survival. CONCLUSION: p53 status along with age and grade appear to be independent prognostic factors for survival in patients with epithelial ovarian cancer.     

Prognostic significance of p53 and Bcl-2 in acute lymphoblastic leukemia

p53 and Bcl-2 protein accumulation and mutations have been found in a wide variety of cancers including different types of leukemia, with varying frequencies. The objective of our study is to find out the correlation between p53 and Bcl-2 protein expression with respect to overall survival of patient taking clinical features and hematological parameters into consideration. Acute lymphoblastic leukemia (ALL) patients, 100 de novo and 10 relapse, were investigated taking different percentage of stained lymphocytes of patients into consideration. Immunocytochemistry and western blot analysis were used to investigate protein expression. PCR-SSCP technique was used to detect point mutations in exon 5, 6, 7 and 8 of p53 gene. P53 protein expression is of prognostic significance in univariate analysis and when combine with Bcl-2 expression data it provides additional information about overall survival. p53 and Bcl-2 failed to provide additional prognostic information in multivariate analysis. None of the samples shows mutation in exon 5, 6, 7 and 8 of p53 gene. Contrary to previous reports, p53 negativity was associated with lower relapse-free survival. Lower p53 expression was associated with improved disease-free survival. The correlation of p53 and Bcl-2 expression data with respect to clinical outcome may shed new sight into the biological significance of p53/Bcl-2 protein.     

Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma

The products of bcl-2 and p53 genes are involved in the regulation of apoptosis and proliferation and have been associated with prognosis in several malignancies, including colorectal adenocarcinoma. Although 2 European studies have reported a prognostic significance of Bcl-2 expression in colorectal adenocarcinomas, a study from the United States did not observe such an association. Therefore, we used immunohistochemistry to evaluate the prognostic significance of Bcl-2 expression, p53 nuclear accumulation and their concomitant expression in 134 US patients with colorectal adenocarcinoma. Antigen retrieval was required for adequate detection of Bcl-2 expression. Fifty percent of the colorectal tumors were classified as expressing Bcl-2, and Bcl-2 expression was associated with longer patient survival. Antigen retrieval was not necessary for detecting nuclear accumulation of p53 by immunohistochemistry. Nuclear accumulation of p53 was detected in 44% of colorectal adenocarcinomas and was associated with decreased patient survival. Tumors that did not express detectable levels of Bcl-2 but exhibited nuclear accumulation of p53 were associated with the shortest patient survival (log rank, p = 0.001). Multivariate Cox regression analysis demonstrated that Bcl-2 expression (p = 0.018), p53 nuclear accumulation (p = 0.024) and regional lymph-node metastasis (p = 0.005) were independent prognostic factors. Although a trend toward an inverse correlation between Bcl-2 and p53 expression was observed, the prognostic value of Bcl-2 expression was independent of p53 status. Thus, assessment of both Bcl-2 and p53 status may be valuable in predicting the prognosis of patients with colorectal adenocarcinomas. Int. J. Cancer 74:346–358, 1997. © 1997 Wiley-Liss, Inc.     

Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer

BACKGROUND: Although the TNM stage is the most important prognostic factor for gastric cancer, there is a need for new prognostic and predictive factors, because the prognosis varies among patients of the same stage. The purpose of this study was to clarify the relationship of p53, nm23, proliferating cell nuclear antigen (PCNA) and c-erbB-2 with the clinicopathological parameters and the survival results. METHODS: For 841 patients who had undergone gastrectomy for gastric cancer at Seoul National University Hospital from July 1996 to December 1997, the expression levels of p53, nm23, PCNA and c-erbB-2 in gastric cancer tissues were examined immunohistochemically. Also, the clinicopathological parameters such as gender, age, operation type, TNM stage and size of the tumor, histology and Lauren classification were analyzed retrospectively. RESULTS: There were 568 males and 273 females (2.07:1) with a mean age of 56 years (range:25-82 years). The percentages of positive expression of p53, nm23 and c-erbB-2 were 43, 74 and 17%, respectively; 59% of tumors expressed PCNA index > or =50. p53 expression was associated with age, gender, tumor size, histology, Lauren classification, stage, nm23 expression, PCNA index >or =50 and c-erbB-2 expression. nm23 expression was associated with age, tumor size, Borrmann type, histology, Lauren classification and stage. PCNA index > or =50 was associated with age, gender, tumor size, Borrmann type, histology, Lauren classification and c-erbB-2 expression. c-erbB-2 expression was associated with gender, Borrmann type, histology and Lauren classification. p53 and nm23 were related with poor prognosis in univariate analysis. nm23 was related with poor prognosis of stage III and diffuse-type gastric cancer in univariate subgroup analysis. However, in a multivariate study, these prognostic impacts were not maintained. CONCLUSION: The expression of p53 and nm23 seems to be related with poor prognosis of gastric cancer patients who have undergone gastrectomy. However, the prognostic significance was not revealed by a multivariate analysis.     

mtp53、p16、Bcl-2蛋白表达与肺癌临床病理关系的研究

目的　探讨mtp53、p16、Bcl2的异常表达与肺癌发生、发展之间的关系。方法　用免疫组化法对114例肺癌组织中mtp53、p16、Bcl2蛋白的表达进行半定量研究,并以14例正常肺组织作对照。结果　mtp53蛋白阳性表达率与肺癌组织学类型和组织学分级无明显关系(P>0.05),与淋巴结转移有密切关系(P<0.05)。p16蛋白阳性表达率与肺癌细胞分化程度和淋巴结转移有密切关系(P<0.05),但与肺癌组织学类型无明显关系(P>0.05)。Bcl2蛋白阳性表达率在小细胞肺癌显著高于非小细胞肺癌(P<0.05)。结论　mtp53、p16、Bcl2在肺癌发生、发展过程中起重要的调控作用     

Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.

BACKGROUND AND PURPOSE: In a recent study on patients with transitional cell cancer of the bladder treated with curative radiotherapy following TUR-T, we demonstrated that a low apoptotic index and p53 positivity were associated with poor local control. The purpose of this study was to assess the prognostic significance of additional markers implicated in regulation of cell cycle and apoptosis. PATIENTS AND METHODS: Bcl-2, Bax and p21 positivity were detected immunohistochemically on paraffin-embedded pre-treatment biopsies from 83 patients with invasive transitional cell cancer (TCC) of the bladder, treated with radiotherapy. In addition, markers determined in an earlier analysis, i.e.: p53, apoptotic index, cyclin D1, retinoblastoma protein and Ki-67 were included in the multivariate analysis. A stepwise proportional hazard analysis was performed, adjusting for classic prognostic factors (T-stage, grade, multifocality and macroscopic completeness of the TUR). Positivity was defined as >10% of tumor cells staining positive for Bcl-2, Bax and p21, and >20% for p53. RESULTS: Bcl-2 positivity was found in 63%, Bax was positive in 52% and p21 in 55% of cases. In the PH analysis Bcl-2 positivity was found to be related to poor local control (36 vs. 72% at 3 years; P=0.003), as well as to shorter disease-specific survival (74 vs. 94% at 3 years; P=0.017). Evidence for an adverse effect of p53 positivity was also found (local control: 32 vs. 69% at 3 years;P=0.037, disease-specific survival: 76 vs. 92% at 3 years; P=0.043). In an additional PH analysis, we found poor local control rates for bladder cancers with combined Bcl-2 and p53 positivity (17 vs. 65% at 3 years; P=0.0017), and lower disease specific survival (60 vs. 92%; P=0.0024), disease-free survival (7 vs.35%, P=0.0023) and overall survival (39 vs. 80%; P=0.0018). CONCLUSION: This study provides evidence for a poor outcome in patients treated with radiotherapy for TCC of the bladder expressing both Bcl-2 and p53. This relationship was found for local control and disease-free, disease-specific and overall survival.     

Prognostic significance of p53 protein expression in early gastric cancer

Mutations of the p53 tumor suppressor gene have been associated with abnormalities in cell cycle regulation, DNA repair and synthesis, apoptosis, and it has been implicated in the prognosis of advanced gastric cancer. The aim of this study was to evaluate the occurrence of p53 gene mutation and its possible prognostic implications in early gastric cancer. In a retrospective study, we studied 80 patients with early gastric cancer treated surgically between 1982 and 2001. Mutation of p53 gene was investigated in surgical gastric specimens by immunohistochemistry, and results were analyzed in relation to gender, age, macroscopic appearance, size and location of tumor, presence of lymph nodes, Lauren’s histological type, degree of differentiation, and the 5-year survival. The expression of p53 was more frequent among the intestinal type (p = 0.003), the differentiated (p = 0.007), and the macroscopically elevated tumors (p = 0.038). Nevertheless, the isolated expression of p53 was not associated with the 5-year survival, or with the frequency of lymph node involvement. The degree of differentiation was detected as an independent factor related to the outcome of patients (0.044). Significantly shorter survival time was found in p53-negative compared with p53-positive patients, when considering the degree of differentiation of tumors, as assessed by Cox regression analysis (0.049). The association of p53 with the intestinal type, the degree of differentiation and morphological characteristics, may reflect the involvement of chronic inflammatory process underlying early gastric cancer. In this population sample, the expression of p53 alone has no prognostic value for early gastric cancer. However, the significant difference in p53 expression between subgroups of degree of differentiation of tumors can influence post-operative outcome of patients and may be related to possible distinct etiopathogenic subtypes.     

Prognostic significance of p53 gene alterations in node-negative breast cancer

Summary Mutations in the p53 gene can play a role in the transformation of normal to malignant cells. Because these mutations are more frequently reported later in the course of transformation, their presence could reflect a greater malignant potential of the tumor and, thus, an increased probability of metastasis and recurrence after local therapy. In a pilot study using single-stranded conformation polymorphism analysis (SSCP), 200 node-negative breast tumors were examined for mutations in the region encompassing exons 5 through 9 of the p53 gene. Exons 5 through 9 were tested because they contain 80–90% of known p53 gene mutations. The tumors ranged in size from 1 to 3 cm. 28 tumors were found to have an abnormal band pattern on both initial and repeat analysis. 4 of these tumors were sequenced; 3 contained a p53 mutation and the 4th had a rare neutral polymorphism. Disease-free survival (DFS) at 5 years for women with tumors having an abnormal SSCP analysis was 57% (± 10%), compared to a 79% (± 3%) DFS for the group with a normal pattern. By the log rank test, this difference was highly significant, p 0.01. The relative risk of recurrence for the group with an abnormal SSCP pattern was 2.2. In a multivariate analysis including ER, PgR, ploidy, S-phase, age, and tumor size, an abnormal p53 by SSCP analysis and patient age were the only factors that independently predicted DFS at 5 years. Conclusion: Women with node-negative breast cancer who have tumors with alterations in the p53 gene, as indicated by SSCP analysis, have a significantly poorer prognosis and a higher rate of relapse at 5 years. The prognostic significance is maintained in a multivariate analysis including many established prognostic factors.We regret to report that Dr. McGuire died March 25, 1992, while this work was in progress.     

Survivin、p53、Bcl-2蛋白在非小细胞肺癌中的表达及意义

目的:探讨Survivin基因在非小细胞肺癌(NSCLC)中的表达,以及与P53,Bcl-2蛋白表达的相互关系。方法:应用免疫组织化学法(SP)检测80例NSCLC肿瘤组织、20例肺良性病变组织中Survivin蛋白、P53蛋白、Bcl-2蛋白表达情况,并将结果进行了相关分析。结果:Survivin蛋白在肺良性病变组织中不表达,在61.3%(49/80)的NSCLC组织中有表达,且Survivin的表达与肺癌患者的TNM分期有关,但与肺癌的细胞类型、分化程度及淋巴结转移无明显关系;肺癌组织p53蛋白阳性表达率55.0%(44/80),与肺癌的TNM分期及淋巴结转移有关,肺良性病变组织中无p53蛋白表达;肺癌组织Bcl-2蛋白阳性表达率50.0%(40/80)明显高于肺良性病变组织的10.0%(2/20),其中鳞癌组织的表达率62.2%,明显高于腺癌组织的表达率34.3%(P<0.05);肺癌组织中P53,Bcl-2蛋白与Survivin蛋白表达显著相关(P<0.05)。结论:Survivin蛋白在肺癌组织中表达上调,提示该基因对NSCLC的发生发展起重要作用。Survivin基因有望成为肺癌基因治疗的新靶点;Survivin蛋白表达与肺癌的TNM分期密切相关,提示可作为判断病情和评价预后的指标。Sur vivin蛋白的表达与p53蛋白、Bcl-2蛋白的表达均呈正相关,三者在肺癌的发生中可能起协同作用。     

Prognostic significance of mutations in the p53 gene in superficial bladder cancer

Bladder tumors as the most common urologic malignancy present mostly as superficial transitional cell carcinoma. Many patients with superficial bladder cancer have a good prognosis, however, may develop recurrences or progress to muscle invasive or metastatic disease. It is therefore important to find new markers associated with the biological behaviour of an individual tumor for identifying patients at risk for disease progression. Previous reports on the prognostic significance of p53 alterations in bladder tumors revealed conflicting results. The aim of our study was to evaluate p53 mutation analysis as an effective concept for the characterization of subsets of superficial bladder tumors differing in biological aggressiveness. Screening 66 amplified DNA from micro-dissected tumor cells by direct genomic sequencing p53 alterations were detected in 12%. We found no association between p53 status and tumor stage but a tendency to a higher mutation rate in more malignant tumors (G2 and G3) compared to G1 tumors and a higher recurrence rate in patients with a p53 mutation in the primary tumor after 24 months follow-up. We conclude a general low incidence of p53 mutations in superficial bladder cancer. Detectable p53 damage might be related to a more aggressive phenotype and a higher recurrence risk. Our results are discussed in the context of other studies reviewed from 1995-2000.     

Prognostic significance of p53 mutations in colon cancer at the population level

Some studies have reported that p53 mutations or certain types of p53 mutation are associated with poor prognosis in colon cancer, while other studies have failed to show such a relationship. None of these previous studies was population-based. We therefore evaluated the prognostic significance of p53 mutations in a large, population-based study of 1,464 individuals with colon cancer from Utah and California. Mutations in exons 5-8 were detected by SSCP analysis, followed by sequencing of aberrant bands. p53 mutations were identified in colon cancers from 665 of 1,464 (45.4%) individuals. p53 mutations were significantly more common in distal tumors (p < 0.01), tumors of relatively high stage (p = 0.04), tumors without MSI (p < 0.01) and tumors without Ki-ras mutations (p < 0.01). In a univariate analysis, tumors with p53 mutations were associated with a significantly worse 5-year survival than those with wild-type p53 (53.4% vs. 58.8%, p = 0.04); significantly worse prognosis also was seen with missense mutations, transitions, transversions, mutations affecting the structure of the p53 molecule, mutations within the beta-sandwich motif and mutations in proximal tumors. In multivariate analyses, however, the only significant predictors of poor prognosis were G245 hot spot mutations (HRR = 2.16, 95% CI 1.06-4.40) and p53 mutations in proximal tumors (HRR = 1.34, 95% CI 1.07-1.63). We conclude that overall p53 mutational status is not an independent predictor of poor prognosis in colon cancer. However, specific classes of mutations, namely, the G245 hot spot mutation and mutations in proximal tumors, are related to significantly worse survival even after adjusting for age and stage.     

Immunohistochemical detection of p53 and c-erbB-2 proteins: Prognostic significance in operable breast cancer

We examined the associations of p53 expression and/or c-erbB-2 expression with Ag-NOR counts and clinicopathologic variables in 111 breast cancer patients, and assessed whether expression of either p53 or c-erbB-2 would be useful prognostic indicators. There was no significant association between p⁵³ expression and c-erbB-2 expression, but p53 expression and c-erbB-2 expression, especially in combination, were shown to be significantly associated with Ag-NOR counts and axillary lymph node metastasis. Although p⁵³ expression and c-erbB-2 expression were significant prognostic factors by univariate analysis, they did not appear to be independent prognostic factors by multivariate analysis, in which nodal status was introduced using the Cox model. When nodal status was excluded from the model, however, concurrent p⁵³ and c-erbB-2 expression did have a significant prognostic value. Therefore, it was suggested that concurrent p⁵³ and c-erbB-2 expression provides valuable prognostic information for breast cancer patients in whom axillary lymph node dissection has not been performed.     

Prognostic role of apoptotic,Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies

OBJECTIVE: The clinical characteristics and survival probability rate of 36 patients with salivary gland malignancies and 10 patients with benign salivary tumors were summarized in relation to the immunohistological analysis of the tumor, apoptotic-related markers and apoptosis rate. The expression of the markers examined - Bcl-2, c-erbB-2, p53 - was detected in paraffin sections of the tumors by the streptavidin-biotin peroxidase method following heat-induced antigen retrieval, and the apoptosis rate was determined by the TUNEL method. RESULTS: The overall 5-year survival probability was 61% for patients with malignant tumors and 100% for those with benign tumors. The survival probability of patients over 60 at diagnosis was significantly lower than that of younger patients. Patients whose malignant tumors were larger than 2 cm at diagnosis had worse survival than those with smaller tumors. The survival probability of patients whose malignant tumors were located in the submandibular glands was significantly lower than that of patients whose malignancies were located in the parotid and minor salivary glands. The survival probability of patients who demonstrated positive staining for c-erbB- 2 or TUNEL was lower than for those with negative staining. Gender, the existence of concomitant non-salivary malignancies and ethnic origin had no significant impact on survival. CONCLUSIONS: Our results demonstrated significant positive staining in the salivary tumorigenic tissue but not in the surrounding non-tumorigenic tissue examined for TUNEL, c-erbB-2, Bcl-2 and p53, pointing to a biological role for all four markers in the tumorigenic process which is yet to be elucidated. Significant reduction in survival was related to the specific location of the tumor in the submandibular gland, its size and older age of patient. Survival was also found to be significantly reduced when positive staining was demonstrated in the tumor tissue for TUNEL or c-erbB-2, more so for concomitant positive staining of both markers. Clinically, the most important result of the current study is that the survival rate of the patients examined with salivary tumors larger than 2 cm, with positive staining for both TUNEL and c-erbB-2, was 0 (p = 0.0001)!     

Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma

BACKGROUND: Nasopharyngeal carcinoma (NPC) is consistently associated with Epstein-Barr virus (EBV) infection. EBV-encoded LMP1, expressed in most of NPC, has been suggested to have an important role in the pathogenesis and development of NPC and its expression correlates with poor prognosis. MATERIALS AND METHODS: Eighty-seven NPC biopsies were analyzed by immunohistochemistry for expression of markers of cell proliferation, apoptosis, infiltrating T lymphocytes and macrophages in relation to the LMP1 status. RESULTS: Our findings indicate that the p53 accumulation in NPC was significantly correlated to LMP1 and MMP9 overexpression in NPC cells. The frequency of apoptotic cells in NPC, as analyzed by TUNEL labeling, correlated to Fas-L and caspase-3 expression, and inversely to LMP1, p53 and MMP 9 expression. CD8+ T cell infiltration was predominately seen in nests of cancer cells with a high level of EBV-LMP1 expression, but these CD8+ T cells showed low expression of CD25 and TIA-1, indicating that they were not activated. CONCLUSION: Our observation suggests that the heavy infiltration by lymphocytes in LMP1-positive NPC tumors does not appear to counteract tumor growth by cytoxicity as indicated by the low apoptotic index. Thus, LMP1 seems to enhance survival- and proliferation-related signals in NPC. In analogy with other tumors, both the infiltrating T cells and the accumulated p53 may be inactive.     

EBV相关性胃癌罕见p53基因突变的可能机制与意义

2014年癌症基因组图谱（The Cancer Genome Atlas,TCGA）首次将胃癌从分子水平分为四型,其中EB病毒（Epstein-Barr virus,EBV）感染型即EBV相关性胃癌（EBV-associated gastric cancer,EBVaGC）患者,可能是免疫治疗的适宜群体。在包括胃癌在内的大部分肿瘤中p53基因突变率最高,但在EBVaGC中p53基因突变率却远低于EBV阴性胃癌（EBV-negative gastric cancer,EBVnGC）。可能机制为:EBV感染是EBVaGC形成的早期事件;野生型p53蛋白与病毒即刻早期蛋白BZLF1（Z）相互作用,维持EBV潜伏感染状态和早期复制;病毒复制后期,野生型p53蛋白可在病毒产物的作用下通过泛素化等途径被降解,以上或可表明p53基因野生型对EBVaGC形成的重要性。而EBV感染诱导炎症反应,肿瘤组织中大量淋巴细胞浸润,基因组高突变率及PD-L1扩增的特征使其可能成为免疫治疗的适宜群体,也说明免疫微环境在肿瘤发生发展中的重要作用。而在EBVnGC中,多种因素导致p53基因突变率较高,使其失去正常的抑癌功能而导致肿瘤发生。本文就EBVaGC中罕见p53基因突变这一现象的可能机制进行综述。      

Epstein-Barr virus and nasopharyngeal carcinoma.

Nasopharyngeal carcinoma, an epithelial tumor which is characterized by marked geographic and population differences in incidence, is consistently associated with the Epstein-Barr virus (EBV). Within the tumor, the EBV DNA is homogeneous and clonal with regard to repeat sequences suggesting that the tumor is also clonal. Expression of specific viral mRNAs or gene products are consistently detected within all of the tumor cells. These data suggest that EBV is an essential component in the development of nasopharyngeal carcinoma. Genetic or environmental co-factors may influence the ability of the virus to express these genes in infected epithelial tissue or may contribute to clonal predominance.     

p16、p53、BRAF、Bcl-2在卵巢浆液性肿瘤组织中的表达及临床意义

目的:探讨卵巢浆液性肿瘤组织中p16、p53、BRAF、Bcl-2的表达及临床意义。方法:收集宁夏医科大学总医院病理科2017年至2018年确诊的卵巢浆液性肿瘤136例,其中浆液性囊腺瘤52例,交界性囊腺瘤22例,低级别浆液性癌18例,高级别浆液性癌44例;另收集卵巢良性肿瘤和卵巢癌手术切除标本各30例。分别采用免疫组织化学SP法检测p16、p53、BRAF、Bcl-2的表达,实时定量PCR法检测p16、p53在卵巢良恶性肿瘤组织中的表达。结果:卵巢浆液性囊腺瘤、交界性囊腺瘤、低/高级别浆液性癌组织中p16的阳性率分别为3.8%、45.5%、88.9%、81.8%,p53为0、9.1%、55.6%、45.5%,BRAF为46.2%、45.5%、22.2%、31.8%,Bcl-2为46.2%、45.5%、38.9%、47.7%。不同类型浆液性肿瘤组织中p16、p53表达均有显著性差异（P＜0.001）,但BRAF、Bcl-2表达未见明显差异。与卵巢良性肿瘤相比,p16在交界性肿瘤、卵巢癌中的阳性表达明显升高,差异有显著统计学意义（P＜0.012 5）;p53在卵巢癌中的阳性表达明显高于良性肿瘤（P＜0.001）;p16和p53的表达呈正相关（P＜0.05）。p53、Bcl-2与卵巢癌淋巴结转移有相关性（P＜0.001）,p16、p53、Bcl-2与盆腔侵犯有关（P＜0.05）,p53、BRAF、Bcl-2与CA125表达有不同程度相关性（P＜0.05）。p16、p53联合检测对卵巢癌诊断的敏感性和特异性为90.0%、76.7%。结论:p16、p53、BRAF、Bcl-2参与卵巢癌的发生发展,p16和p53基因突变可能在卵巢浆液性肿瘤的恶性进展中发挥作用,联合检测p16、p53对卵巢癌诊断有指示意义。     

Bcl-2、p53和ki-67在甲状腺癌中的表达及其临床意义的研究

目的：研究甲状腺癌组织中Bcl-2、p53和ki-67的表达及其临床意义。方法：采用免疫组织化学SP法检测甲状腺癌组织、甲状腺腺瘤和正常甲状腺中Bcl-2、p53和ki-67的表达情况。结果：Bcl-2、p53和ki-67的阳性表达见于甲状腺癌组织和甲状腺腺瘤中,正常甲状腺组织中未见三者的阳性表达。甲状腺癌组织中Bcl-2的阳性表达率明显高于腺瘤组织（ P＜0.05）,甲状腺癌组织中p53的阳性表达率明显高于腺瘤组织（P＜0.05）,ki-67在甲状腺癌中的阳性表达率为71.3％,高于甲状腺腺瘤10.0％（P＜0.05）。甲状腺未分化癌和滤泡状癌组织中Bcl-2的阳性率明显增高。有淋巴结转移和临床Ⅲ、Ⅳ期病例中,Bcl-2的阳性率明显增高。结论：Bcl-2、p53和ki-67在甲状腺癌发生发展中起重要作用,Bcl-2、p53和ki-67的表达可作为甲状腺癌预后的指标。